CA-DC-CONNECTED-CAR
DC Connected Car GmbH, a trailblazer in AI-driven remote vehicle diagnostics, announces the closure of a €2.1M seed funding round. Led by Insurtech-fund VENPACE, this round includes contributions from Borusan Ventures, Atlas Ventures, Network.VC, and existing investors APX, Bloomhaus Ventures, and Business Angels. This investment accelerates DC Connected Car's mission to revolutionize the $500B automotive aftersales market with its virtual technician platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807187434/en/
This fresh injection of capital will fuel DC Connected Car's international expansion and development of advanced diagnostic tools for roadside assistance, warranty, and repair. (Graphic: Business Wire)
DC Connected Car's virtual technician platform addresses the shortage of skilled labor in the industry, and their remote diagnostics and advanced AI set new sector benchmarks. Unlike conventional diagnostics, AI-driven solutions deliver automated, intelligent insights into vehicle health and performance, providing real-time problem-solution recommendations. This approach minimizes the need for physical inspections/repairs, but also integrates into customers' lives by offering remote support. By combining AI with remote diagnostics, DC Connected Car redefines vehicle maintenance and customer convenience, solidifying its position as a standout player in the space, highlighted by its partnerships with Major OEMs.
"AI has the potential to revolutionize various automotive areas that Borusan operates in, such as aftersales, fleets, and used car business," said Timo Kilp, Head of Borusan Ventures. "We believe DC Connected Car's AI-driven digital technician holds significant promise to accelerate the diagnosis and repair of vehicle issues, further enhancing our customer service."
Not only disruptive in the automotive repair sector, DC Connected Car is driving innovations in the insurance industry too. Their partnership with Real Garant Versicherung AG marks a new era of digitalization, sustainable mobility, and future-orientated service design.
"With the cooperation with DC Connected Car GmbH, we expect to significantly contribute to environmentally friendly mobility solutions and to drive forward digitalization in the automotive sector by providing digital solutions for warranty and service products,” explains Suzana Janny, Head of Market Proposition at Real Garant Versicherung AG.
This fresh injection of capital will fuel DC Connected Car's international expansion and development of advanced diagnostic tools for roadside assistance, warranty, and repair. The company has seamlessly integrated and digitized expertise across various automotive departments, breaking down silos and enhancing efficiency.
About DC Connected Car GmbH
Founded in 2020 in Leibi, Germany, DC Connected Car offers an all-in-one solution that represents the virtual vehicle technician of the future. This platform addresses the complexities of modern vehicle generations and labor shortage by enabling automated and intelligent diagnostic and repair processes.
"What excites us most about DC Connected Car is the wide range of possible applications for their virtual assistant in the mobility ecosystem. Insurers especially have a high interest in elevating their customer experience by digitizing roadside assistance services. In addition, the team has already impressively demonstrated that it has been able to win well-known B2B customers and OEMs as partners," said Tizian Hoppen of VENPACE.
The team behind DC Connected Car includes experts with deep industry knowledge and experience. Dennis Christ, an expert in automotive technology and a certified appraiser, provides precise and reliable diagnostic procedures. Ralf Schollenberger leverages his extensive network and expertise in insurance and the aftermarket to forge strategic partnerships. Willian Servigna, specializing in AI and software development, ensures that solutions remain at the forefront of technology.
About VENPACE - VENPACE is a leading investor from the insurance space, guiding startups with unique expertise to sustainably scale innovative solutions. Together with partners throughout the DACH region, they tackle the insurance industry’s challenges head-on, developing and establishing innovative business models.
About BORUSAN Ventures - Borusan Ventures is the corporate venture capital arm of Borusan Group, a prominent industrial group in the U.S., Europe and CIS region. Headquartered in Silicon Valley, Borusan Ventures invests in early-stage startups in the U.S. and Europe, focusing on mobility, supply chain/logistics, energy/climate, enterprise, and industrial sectors.
About ATLAS Ventures - Atlas Ventures is a UK-based industrial tech fund focussed on investing in seed and late seed stage opportunities in Developed European markets, with a primary focus on innovative B2B solutions targeting industrial manufacturing, energy and climate, mobility, supply chain and logistics sectors.
For more information, visit https://www.dc-connected.de/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807187434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom